Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia Maria, 1981-
  • Barallobre, María José
  • Di Vona, Chiara, 1981-
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera, Mariona
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Luna Gargantilla, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis., This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), “La Marató de TV3” to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European CommissionFP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Skłodowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011-045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011-11140), and A.F.F. is a Marie Skłodowska-Curie ESR fellow.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response

  • Roewenstrunk, Julia Maria, 1981-
  • Di Vona, Chiara, 1981-
  • Chen, Jie
  • Borràs, Eva
  • Dong, Chao
  • Arató, Krisztina, 1981-
  • Sabidó Aguadé, Eduard, 1981-
  • Huen, Michael S. Y.
  • Luna Gargantilla, Susana de la
Dysregulation of the DYRK1A protein kinase has been associated with human disease. On the one hand, its overexpression in trisomy 21 has been linked to certain pathological traits of Down syndrome, while on the other, inactivating mutations in just one allele are responsible for a distinct yet rare clinical syndrome, DYRK1A haploinsufficiency. Moreover, altered expression of this kinase may also provoke other human pathologies, including cancer and diabetes. Although a few DYRK1A substrates have been described, its upstream regulators and downstream targets are still poorly understood, an information that could shed light on the functions of DYRK1A in the cell. Here, we carried out a proteomic screen using antibody-based affinity purification coupled to mass spectrometry to identify proteins that directly or indirectly bind to endogenous DYRK1A. We show that the use of a cell line not expressing DYRK1A, generated by CRISPR/Cas9 technology, was needed in order to discriminate between true positives and non-specific interactions. Most of the proteins identified in the screen are novel candidate DYRK1A interactors linked to a variety of activities in the cell. The in-depth characterization of DYRK1A's functional interaction with one of them, the E3 ubiquitin ligase RNF169, revealed a role for this kinase in the DNA damage response. We found that RNF169 is a DYRK1A substrate and we identified several of its phosphorylation sites. In particular, one of these sites appears to modify the ability of RNF169 to displace 53BP1 from sites of DNA damage. Indeed, DYRK1A depletion increases cell sensitivity to ionizing irradiation. Therefore, our unbiased proteomic screen has revealed a novel activity of DYRK1A, expanding the complex role of this kinase in controlling cell homeostasis., This work was supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) BFU2013-44513 and BFU2016-76141-P, and the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674). Proteomic analysis was carried out at the CRG/UPF Proteomics Unit, a member of the ProteoRed PRB3 consortium that is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. J.R. is a FPI predoctoral fellow (BES-2011-045867). We also acknowledge the support of the Generalitat de Catalunya: CERCA Programme and Grups de Recerca Reconocida Programme (2017SGR595 and 2017SGR1163)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase

  • Vona, Chiara Di
  • Bezdan, Daniela
  • Islam, Abul, 1978-
  • Salichs Fradera, Eulàlia
  • López Bigas, Núria
  • Ossowski, Stephan
  • Luna, Susana de la
DYRK1A is a dosage-sensitive protein kinase that fulfills key roles during development and in tissue homeostasis, and its dysregulation results in human pathologies. DYRK1A is present in both the nucleus and cytoplasm of mammalian cells, although its nuclear function remains unclear. Genome-wide analysis of DYRK1A-associated loci reveals that the kinase is recruited preferentially to promoters of genes actively transcribed by RNA polymerase II (RNAPII), which are functionally associated with translation, RNA processing, and cell cycle. DYRK1A-bound promoter sequences are highly enriched in a conserved palindromic motif, which is necessary to drive DYRK1A-dependent transcriptional activation. DYRK1A phosphorylates the C-terminal domain (CTD) of RNAPII at Ser2 and Ser5. Depletion of DYRK1A results in reduced association of RNAPII at the target promoters as well as hypophosphorylation of the RNAPII CTD along the target gene bodies. These results are consistent with DYRK1A being a transcriptional regulator by acting as a CTD kinase., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO: BFU2010-15347, BFU2013-44513 to S.d.l.L., SAF2012-36199 to N.L.-B., and ‘Centro de Excelencia Severo Ochoa 2013-2017’-SEV-2012-0208) and the Secretariat of Universities and Research-Government of Catalonia (2014SGR674 to S.d.l.L.). C.D.V. and E.S. were FPI predoctoral fellows financed by MINECO (BES2008-002751 and BES2005-10136)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

  • Arranz, Juan
  • Balducci, Elisa, 1981-
  • Arató, Krisztina, 1981-
  • Sánchez-Elexpuru, Gentzane
  • Najas Sales, Sònia, 1985-
  • Parras, Alberto
  • Rebollo, Elena
  • Pijuan, Isabel
  • Erb, Ionas
  • Verde, Gaetano
  • Sahún, Ignasi
  • Barallobre, María José
  • Lucas, José J.
  • Sánchez, Marina P.
  • de la Luna, Susana
  • Arbonés de Rafael, Maria Lourdes, 1959-
Autism spectrum disorders are early onset neurodevelopmental disorders characterized by deficits in social communication and restricted repetitive behaviors, yet they are quite heterogeneous in terms of their genetic basis and phenotypic manifestations. Recently, de novo pathogenic mutations in DYRK1A, a chromosome 21 gene associated to neuropathological traits of Down syndrome, have been identified in patients presenting a recognizable syndrome included in the autism spectrum. These mutations produce DYRK1A kinases with partial or complete absence of the catalytic domain, or they represent missense mutations located within this domain. Here, we undertook an extensive biochemical characterization of the DYRK1A missense mutations reported to date and show that most of them, but not all, result in enzymatically dead DYRK1A proteins. We also show that haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits associated with the human pathology, such as defective social interactions, stereotypic behaviors and epileptic activity. These mutant mice present altered proportions of excitatory and inhibitory neocortical neurons and synapses. Moreover, we provide evidence that alterations in the production of cortical excitatory neurons are contributing to these defects. Indeed, by the end of the neurogenic period, the expression of developmental regulated genes involved in neuron differentiation and/or activity is altered. Therefore, our data indicate that altered neocortical neurogenesis could critically affect the formation of cortical circuits, thereby contributing to the neuropathological changes in DYRK1A haploinsufficiency syndrome., This work was supported by grants from the Spanish Ministry of Economia, Industria y Competitividad (MINECO) (BFU2016-81887-REDT, SAF2013-46676-P and SAF2016-77971-R to M.L.A. and BFU2013-44513 and BFU2016-76141 to S.L.), the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), and the Fundación Alicia Koplowitz (Spain). The group of S.L. acknowledges the support of the MINECO Centro de Excelencia Severo Ochoa Programme and of the CERCA Programme (Generalitat de Catalunya). G.S-E. and M.P.S. acknowledge the support of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health(USA) (P01NS097197) and the Spanish Instituto de Salud Carlos III (ISCIII), (PI13/00865, Fondo Europeo de Desarrollo Regional -FEDER “A way of making Europe”, Spain). M.J.B. is supported by the CIBERER, an initiative of the ISCIII. J.A., E.B. and S.N. were supported by MINECO predoctoral fellowships (AP2012-3064 and BES2011-047472) and G.S-E. by a predoctoral fellowship from the Fundación Conchita Rábago, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia
  • Barallobre, María-José
  • Di Vona, Chiara
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat, Cristina
  • Arbones, Maria L.
  • Graupera, Mariona
  • Valverde, Miguel A.
  • Luna, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis, This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), ‘‘La Marato´ de TV3’’ to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European Commission FP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Sk1odowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011- 045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011- 11140), and A.F.F. is a Marie Sk1odowska-Curie ESR fellow. We acknowledge the support of the MINECO Centro de Excelencia Severo Ochoa and María de Maeztu Programme and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

  • Arranz, Juan
  • Balducci, Elisa
  • Arató, Krisztina
  • Sánchez-Elexpuru, Gentzane
  • Najas, Sònia
  • Parras, Alberto
  • Rebollo, Elena
  • Pijuan, Isabel
  • Erb, Ionas
  • Verde, Gaetano
  • Sahún, Ignasi
  • Barallobre, María-José
  • Lucas, José Javier
  • Sánchez, Marina P.
  • Luna, Susana de la
  • Arbones, Maria L.
Autism spectrum disorders are early onset neurodevelopmental disorders characterized by deficits in social communication and restricted repetitive behaviors, yet they are quite heterogeneous in terms of their genetic basis and phenotypic manifestations. Recently, de novo pathogenic mutations in DYRK1A, a chromosome 21 gene associated to neuropathological traits of Down syndrome, have been identified in patients presenting a recognizable syndrome included in the autism spectrum. These mutations produce DYRK1A kinases with partial or complete absence of the catalytic domain, or they represent missense mutations located within this domain. Here, we undertook an extensive biochemical characterization of the DYRK1A missense mutations reported to date and show that most of them, but not all, result in enzymatically dead DYRK1A proteins. We also show that haploinsufficient Dyrk1a+/− mutant mice mirror the neurological traits associated with the human pathology, such as defective social interactions, stereotypic behaviors and epileptic activity. These mutant mice present altered proportions of excitatory and inhibitory neocortical neurons and synapses. Moreover, we provide evidence that alterations in the production of cortical excitatory neurons are contributing to these defects. Indeed, by the end of the neurogenic period, the expression of developmental regulated genes involved in neuron differentiation and/or activity is altered. Therefore, our data indicate that altered neocortical neurogenesis could critically affect the formation of cortical circuits, thereby contributing to the neuropathological changes in DYRK1A haploinsufficiency syndrome., This work was supported by grants from the Spanish Ministry of Economia, Industria y Competitividad (MINECO) (BFU2016-81887-REDT, SAF2013-46676-P and SAF2016-77971-R to M.L.A. and BFU2013-44513 and BFU2016-76141 to S.L.), the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), and the Fundación Alicia Koplowitz (Spain). The group of S.L. acknowledges the support of the MINECO Centro de Excelencia Severo Ochoa Programme and of the CERCA Programme (Generalitat de Catalunya). G.S-E. and M.P.S. acknowledge the support of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health(USA) (P01NS097197) and the Spanish Instituto de Salud Carlos III (ISCIII), (PI13/00865, Fondo Europeo de Desarrollo Regional -FEDER “A way of making Europe”, Spain). M.J.B. is supported by the CIBERER, an initiative of the ISCIII. J.A., E.B. and S.N. were supported by MINECO predoctoral fellowships (AP2012-3064 and BES2011-047472) and G.S-E. by a predoctoral fellowship from the Fundación Conchita Rábago, Spain.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia Maria, 1981-
  • Barallobre, María José
  • Di Vona, Chiara, 1981-
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera, Mariona
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Luna Gargantilla, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis., This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), “La Marató de TV3” to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European CommissionFP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Skłodowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011-045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011-11140), and A.F.F. is a Marie Skłodowska-Curie ESR fellow.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

  • Arranz, Juan
  • Balducci, Elisa, 1981-
  • Arató, Krisztina, 1981-
  • Sánchez-Elexpuru, Gentzane
  • Najas Sales, Sònia, 1985-
  • Parras, Alberto
  • Rebollo, Elena
  • Pijuan, Isabel
  • Erb, Ionas
  • Verde, Gaetano
  • Sahún, Ignasi
  • Barallobre, María José
  • Lucas, José J.
  • Sánchez, Marina P.
  • de la Luna, Susana
  • Arbonés de Rafael, Maria Lourdes, 1959-
Autism spectrum disorders are early onset neurodevelopmental disorders characterized by deficits in social communication and restricted repetitive behaviors, yet they are quite heterogeneous in terms of their genetic basis and phenotypic manifestations. Recently, de novo pathogenic mutations in DYRK1A, a chromosome 21 gene associated to neuropathological traits of Down syndrome, have been identified in patients presenting a recognizable syndrome included in the autism spectrum. These mutations produce DYRK1A kinases with partial or complete absence of the catalytic domain, or they represent missense mutations located within this domain. Here, we undertook an extensive biochemical characterization of the DYRK1A missense mutations reported to date and show that most of them, but not all, result in enzymatically dead DYRK1A proteins. We also show that haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits associated with the human pathology, such as defective social interactions, stereotypic behaviors and epileptic activity. These mutant mice present altered proportions of excitatory and inhibitory neocortical neurons and synapses. Moreover, we provide evidence that alterations in the production of cortical excitatory neurons are contributing to these defects. Indeed, by the end of the neurogenic period, the expression of developmental regulated genes involved in neuron differentiation and/or activity is altered. Therefore, our data indicate that altered neocortical neurogenesis could critically affect the formation of cortical circuits, thereby contributing to the neuropathological changes in DYRK1A haploinsufficiency syndrome., This work was supported by grants from the Spanish Ministry of Economia, Industria y Competitividad (MINECO) (BFU2016-81887-REDT, SAF2013-46676-P and SAF2016-77971-R to M.L.A. and BFU2013-44513 and BFU2016-76141 to S.L.), the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), and the Fundación Alicia Koplowitz (Spain). The group of S.L. acknowledges the support of the MINECO Centro de Excelencia Severo Ochoa Programme and of the CERCA Programme (Generalitat de Catalunya). G.S-E. and M.P.S. acknowledge the support of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health(USA) (P01NS097197) and the Spanish Instituto de Salud Carlos III (ISCIII), (PI13/00865, Fondo Europeo de Desarrollo Regional -FEDER “A way of making Europe”, Spain). M.J.B. is supported by the CIBERER, an initiative of the ISCIII. J.A., E.B. and S.N. were supported by MINECO predoctoral fellowships (AP2012-3064 and BES2011-047472) and G.S-E. by a predoctoral fellowship from the Fundación Conchita Rábago, Spain.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase

  • Vona, Chiara Di
  • Bezdan, Daniela
  • Islam, Abul, 1978-
  • Salichs Fradera, Eulàlia
  • López Bigas, Núria
  • Ossowski, Stephan
  • Luna, Susana de la
DYRK1A is a dosage-sensitive protein kinase that fulfills key roles during development and in tissue homeostasis, and its dysregulation results in human pathologies. DYRK1A is present in both the nucleus and cytoplasm of mammalian cells, although its nuclear function remains unclear. Genome-wide analysis of DYRK1A-associated loci reveals that the kinase is recruited preferentially to promoters of genes actively transcribed by RNA polymerase II (RNAPII), which are functionally associated with translation, RNA processing, and cell cycle. DYRK1A-bound promoter sequences are highly enriched in a conserved palindromic motif, which is necessary to drive DYRK1A-dependent transcriptional activation. DYRK1A phosphorylates the C-terminal domain (CTD) of RNAPII at Ser2 and Ser5. Depletion of DYRK1A results in reduced association of RNAPII at the target promoters as well as hypophosphorylation of the RNAPII CTD along the target gene bodies. These results are consistent with DYRK1A being a transcriptional regulator by acting as a CTD kinase., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO: BFU2010-15347, BFU2013-44513 to S.d.l.L., SAF2012-36199 to N.L.-B., and ‘Centro de Excelencia Severo Ochoa 2013-2017’-SEV-2012-0208) and the Secretariat of Universities and Research-Government of Catalonia (2014SGR674 to S.d.l.L.). C.D.V. and E.S. were FPI predoctoral fellows financed by MINECO (BES2008-002751 and BES2005-10136)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response

  • Roewenstrunk, Julia Maria, 1981-
  • Di Vona, Chiara, 1981-
  • Chen, Jie
  • Borràs, Eva
  • Dong, Chao
  • Arató, Krisztina, 1981-
  • Sabidó Aguadé, Eduard, 1981-
  • Huen, Michael S. Y.
  • Luna Gargantilla, Susana de la
Dysregulation of the DYRK1A protein kinase has been associated with human disease. On the one hand, its overexpression in trisomy 21 has been linked to certain pathological traits of Down syndrome, while on the other, inactivating mutations in just one allele are responsible for a distinct yet rare clinical syndrome, DYRK1A haploinsufficiency. Moreover, altered expression of this kinase may also provoke other human pathologies, including cancer and diabetes. Although a few DYRK1A substrates have been described, its upstream regulators and downstream targets are still poorly understood, an information that could shed light on the functions of DYRK1A in the cell. Here, we carried out a proteomic screen using antibody-based affinity purification coupled to mass spectrometry to identify proteins that directly or indirectly bind to endogenous DYRK1A. We show that the use of a cell line not expressing DYRK1A, generated by CRISPR/Cas9 technology, was needed in order to discriminate between true positives and non-specific interactions. Most of the proteins identified in the screen are novel candidate DYRK1A interactors linked to a variety of activities in the cell. The in-depth characterization of DYRK1A's functional interaction with one of them, the E3 ubiquitin ligase RNF169, revealed a role for this kinase in the DNA damage response. We found that RNF169 is a DYRK1A substrate and we identified several of its phosphorylation sites. In particular, one of these sites appears to modify the ability of RNF169 to displace 53BP1 from sites of DNA damage. Indeed, DYRK1A depletion increases cell sensitivity to ionizing irradiation. Therefore, our unbiased proteomic screen has revealed a novel activity of DYRK1A, expanding the complex role of this kinase in controlling cell homeostasis., This work was supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) BFU2013-44513 and BFU2016-76141-P, and the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674). Proteomic analysis was carried out at the CRG/UPF Proteomics Unit, a member of the ProteoRed PRB3 consortium that is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. J.R. is a FPI predoctoral fellow (BES-2011-045867). We also acknowledge the support of the Generalitat de Catalunya: CERCA Programme and Grups de Recerca Reconocida Programme (2017SGR595 and 2017SGR1163)